“…Thus far, several nanostructures have been studied and introduced for DD and DR purposes: the graphdiyne for sorafenib and regorafenib drugs. 15 Graphene nanosheets, 16,17 BN sheets for 5-fluorouracil (FU), 6-mercaptopurine (MP) and 6-thioguanine (TG) drugs, 18 phosphorene, 19 porphyrin-like porous nanostructures for ibuprofen drugs, 20 BN and graphene nanoflakes, 21 boron nitride nanotubes, nanosheets, and nanoclusters for MP drugs, 22 doped graphene nanocarriers with Al, Si, and B for anti-cancer adrucil, 23 pure graphene nanosheets, Pt-and Au-doped graphene sheets, BC 2 N sheets for the b-lapachone anti-cancer drug, 24,25 BC 3 and C 2 N monolayers, all-boron fullerene B 40 , and pristine and doped (Al, Ga and In) boron nitride nanosheets for nitrosourea anti-cancer drugs, [26][27][28] metal oxide nanoclusters, 29 XC 3 (X = B and N) nanosheets for hydroxyurea (HU) anti-cancer drugs, 30 B 3 O 3 nanosheets for TEPA drug, 31 pristine and metal-doped GNS for (5-FU, 6-MP, GB, and CP) anti-cancer drugs, 32 AlN nanosheets, nanotubes and nanocages for benzoylethanamine drug, 33 pristine and BN-doped graphdiyne nanosheets for HU and FU drugs, 34 g-BC 6 N nanosheets for HU, 5-FU, carmustine (CMU), 6-MP, ifosfamide (IFO), and chloromethane (CM) drugs, 35 BC 3 nanosheets for 6-MP drugs, 36 and Pt-decorated AlN nanosheets for TG anti-cancer drugs. 37 In most of the studies in this field, it was observed that nanocarriers generally have desirable properties for DD by manipulating the structure.…”